MDxHealth SA (MDxHealth) develops and commercializes advanced epigenetic and other molecular tests for cancer assessment, and the personalized treatment of patients. The company’s product portfolio includes ConfirmMDx, an epigenetic assay that detects the epigenetic effect of cancer; SelectMDx, a liquid biopsy assay for prostate cancer. MdxHealth tests are based on MSP (Methylation-Specific polymerase chain reaction) technology, a proprietary DNA-based platform. It also offers biomarker development services to many pharmaceutical companies. MDxHealth markets its products through sales forces, partnerships and distributors. The company has operations in the Netherlands, Belgium, and the US. MDxHealth is headquartered in Herstal, Liege, Belgium.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company MDxHealth SA
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- MDxHealth SA Company Overview
- MDxHealth SA Company Snapshot
- MDxHealth SA Pipeline Products and Ongoing Clinical Trials Overview
- MDxHealth SA - Pipeline Analysis Overview
- Business Description
- MDxHealth SA - Key Facts
- MDxHealth SA - Major Products and Services
- MDxHealth SA Pipeline Products by Development Stage
- MDxHealth SA Pipeline Products Overview
(Epi)genetic Diagnostic Assay - Kidney Cancer Product Overview
- AS-MDx Test
- AS-MDx Test Product Overview
- Bladder ConfirmMDx
- Bladder ConfirmMDx Product Overview
- Bladder RecurMdx
- Bladder RecurMdx Product Overview
- ClinicalMDx - Cervical Cancer
- ClinicalMDx - Cervical Cancer Product Overview
- ConfirmMDx Lung Cancer Test
- ConfirmMDx Lung Cancer Test Product Overview
- Diagnostic Test - Urologic Cancer
- Diagnostic Test - Urologic Cancer Product Overview
- Epigenetic Biomarker Test - Prostate Cancer
- Epigenetic Biomarker Test - Prostate Cancer Product Overview
- InformMDx - Colon Cancer
- InformMDx - Colon Cancer Product Overview
- InformMDx - Prostate Cancer CLIA Test
- InformMDx - Prostate Cancer CLIA Test Product Overview
- InformMDx Prognostic Test - Prostate Cancer
- InformMDx Prognostic Test - Prostate Cancer Product Overview
- Liquid Biopsy Epigenetic Assay - Oral Cancer
- Liquid Biopsy Epigenetic Assay - Oral Cancer Product Overview
- Molecular Diagnostic Test - Bladder Cancer
- Molecular Diagnostic Test - Bladder Cancer Product Overview
- MonitorMDx - Prostate Cancer
- MonitorMDx - Prostate Cancer Product Overview
- PharmacoDx - Breast Cancer
- PharmacoDx - Breast Cancer Product Overview
- PharmacoDx - Lung Cancer
- PharmacoDx - Lung Cancer Product Overview
- PredictMDx - Colon Cancer
- PredictMDx - Colon Cancer Product Overview
- RecurMDx - Prostate Cancer
- RecurMDx - Prostate Cancer Product Overview
- MDxHealth SA - Key Competitors
- MDxHealth SA - Key Employees
- MDxHealth SA - Key Employee Biographies
- MDxHealth SA - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- MDxHealth SA, Recent Developments
- Feb 22, 2023: MDxHealth to Present Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023
- Aug 02, 2022: Mdxhealth Acquires Oncotype DX GPS Prostate Cancer Business from Exact Sciences and Reports Preliminary Half Year 2022 Results
- Aug 26, 2021: MDxHealth Reports Half Year 2021 Results
- May 27, 2021: MDxHealth Announces Results of its Annual and Extraordinary General Shareholders’ Meetings
- Apr 20, 2020: MDxHealth to receive $2.3 million “Paycheck Protection Program” loan under the U.S. CARES Act
- Apr 09, 2020: MDxHealth provides Q1-2020 business update
- Feb 26, 2020: MDxHealth reports financial year 2019 results and provides outlook for 2020
- Nov 11, 2019: MDxHealth provides Q3-2019 business update
- Aug 29, 2019: MDxHealth reports half year 2019 financial results and strategic update
- Aug 26, 2019: MDxHealth announces favorable draft medicare coverage for the SelectMDx test
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- MDxHealth SA Pipeline Products and Ongoing Clinical Trials Overview
- MDxHealth SA Pipeline Products by Equipment Type
- MDxHealth SA Pipeline Products by Indication
- MDxHealth SA, Key Facts
- MDxHealth SA, Major Products and Services
- MDxHealth SA Number of Pipeline Products by Development Stage
- MDxHealth SA Pipeline Products Summary by Development Stage
(Epi)genetic Diagnostic Assay - Kidney Cancer - Product Description
- AS-MDx Test - Product Status
- AS-MDx Test - Product Description
- Bladder ConfirmMDx - Product Status
- Bladder ConfirmMDx - Product Description
- Bladder RecurMdx - Product Status
- Bladder RecurMdx - Product Description
- ClinicalMDx - Cervical Cancer - Product Status
- ClinicalMDx - Cervical Cancer - Product Description
- ConfirmMDx Lung Cancer Test - Product Status
- ConfirmMDx Lung Cancer Test - Product Description
- Diagnostic Test - Urologic Cancer - Product Status
- Diagnostic Test - Urologic Cancer - Product Description
- Epigenetic Biomarker Test - Prostate Cancer - Product Status
- Epigenetic Biomarker Test - Prostate Cancer - Product Description
- InformMDx - Colon Cancer - Product Status
- InformMDx - Colon Cancer - Product Description
- InformMDx - Prostate Cancer CLIA Test - Product Status
- InformMDx - Prostate Cancer CLIA Test - Product Description
- InformMDx Prognostic Test - Prostate Cancer - Product Status
- InformMDx Prognostic Test - Prostate Cancer - Product Description
- Liquid Biopsy Epigenetic Assay - Oral Cancer - Product Status
- Liquid Biopsy Epigenetic Assay - Oral Cancer - Product Description
- Molecular Diagnostic Test - Bladder Cancer - Product Status
- Molecular Diagnostic Test - Bladder Cancer - Product Description
- MonitorMDx - Prostate Cancer - Product Status
- MonitorMDx - Prostate Cancer - Product Description
- PharmacoDx - Breast Cancer - Product Status
- PharmacoDx - Breast Cancer - Product Description
- PharmacoDx - Lung Cancer - Product Status
- PharmacoDx - Lung Cancer - Product Description
- PredictMDx - Colon Cancer - Product Status
- PredictMDx - Colon Cancer - Product Description
- RecurMDx - Prostate Cancer - Product Status
- RecurMDx - Prostate Cancer - Product Description
- MDxHealth SA, Key Employees
- MDxHealth SA, Key Employee Biographies
- MDxHealth SA, Subsidiaries
- Glossary
- MDxHealth SA Pipeline Products by Equipment Type
- MDxHealth SA Pipeline Products by Development Stage
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Epigenomics AG
- Hologic Ltd
- Myriad Genetics Inc
- Agendia NV
- Genomic Health Inc
- OPKO Health Inc
- Beckman Coulter Inc
